- Home
- ETON vs ATAI Comparison
ETON vs ATAI Comparison
Compare ETON & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ATAI
- Stock Information
- Founded
- ETON 2017
- ATAI 2018
- Country
- ETON United States
- ATAI Germany
- Employees
- ETON N/A
- ATAI N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ATAI Health Care
- Exchange
- ETON Nasdaq
- ATAI Nasdaq
- Market Cap
- ETON 329.8M
- ATAI 282.6M
- IPO Year
- ETON 2018
- ATAI 2021
- Fundamental
- Price
- ETON $14.55
- ATAI $1.47
- Analyst Decision
- ETON Strong Buy
- ATAI Strong Buy
- Analyst Count
- ETON 3
- ATAI 3
- Target Price
- ETON $27.67
- ATAI $10.50
- AVG Volume (30 Days)
- ETON 235.8K
- ATAI 1.8M
- Earning Date
- ETON 05-08-2025
- ATAI 05-14-2025
- Dividend Yield
- ETON N/A
- ATAI N/A
- EPS Growth
- ETON N/A
- ATAI N/A
- EPS
- ETON N/A
- ATAI N/A
- Revenue
- ETON $39,011,000.00
- ATAI $308,000.00
- Revenue This Year
- ETON $92.33
- ATAI $65.58
- Revenue Next Year
- ETON $52.62
- ATAI N/A
- P/E Ratio
- ETON N/A
- ATAI N/A
- Revenue Growth
- ETON 23.29
- ATAI N/A
- 52 Week Low
- ETON $3.11
- ATAI $1.03
- 52 Week High
- ETON $18.41
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- ETON 57.21
- ATAI 52.18
- Support Level
- ETON $13.53
- ATAI $1.41
- Resistance Level
- ETON $14.40
- ATAI $1.51
- Average True Range (ATR)
- ETON 0.97
- ATAI 0.12
- MACD
- ETON 0.32
- ATAI 0.03
- Stochastic Oscillator
- ETON 96.19
- ATAI 87.50
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.